(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE

Abstract

Described here are substantially pure (17-β)-3-Oxoandrost-4-en-17-yl tridecanoate compositions, methods of their preparation and uses thereof.

1 . Substantially pure (17-β)-3-Oxoandrost-4-en-17-yl tridecanoate suitable for administration to human subject in need of (17-β)-hydroxy androst-4-en-3-one. 
     
     
         2 . The substantially pure (17-β)-3-Oxoandrost-4-en-17-yl tridecanoate of  claim 1 , that has greater than 90% potency with respect to (17-β)-3-Oxoandrost-4-en-17-yl tridecanoate. 
     
     
         3 . The substantially pure (17-β)-3-Oxoandrost-4-en-17-yl tridecanoate of  claim 1 , that is substantially free of impurities. 
     
     
         4 . The substantially pure (17-β)-3-Oxoandrost-4-en-17-yl tridecanoate of  claim 3 , having 10% or less of total impurities. 
     
     
         5 . The substantially pure (17-β)-3-Oxoandrost-4-en-17-yl tridecanoate of  claim 4 , having 10% or less of total known impurities. 
     
     
         6 . The substantially pure (17-β)-3-Oxoandrost-4-en-17-yl tridecanoate of  claim 4 , having 10% or less of total unknown impurities. 
     
     
         7 . The substantially pure (17-β)-3-Oxoandrost-4-en-17-yl tridecanoate of  claim 4 , having 10% or less of any single known impurity. 
     
     
         8 . The substantially pure (17-β)-3-Oxoandrost-4-en-17-yl tridecanoate of  claim 7 , having 10% or less of beta-hydroxy androst-4-en-3-one. 
     
     
         9 . The substantially pure (17-β)-3-Oxoandrost-4-en-17-yl tridecanoate of  claim 6 , having 2% or less of any single unknown impurity. 
     
     
         10 . The substantially (17-β)-3-Oxoandrost-4-en-17-yl tridecanoate of  claim 1 , comprising less than 50,000 PPM organic solvent. 
     
     
         11 . The human subject of  claim 1 , wherein the human is a male. 
     
     
         12 . The male of  claim 11 , is a hypogonadal male. 
     
     
         13 . A pharmaceutical composition comprising or made from a substantially pure (17-β)-3-Oxoandrost-4-en-17-yl tridecanoate and a pharmaceutically acceptable carrier for administration to human subject in need of (17-β)-hydroxy-4-androsten-3-one. 
     
     
         14 . The pharmaceutical composition of  claim 13 , suitable for dosing up to 2000 mg per day (17-β)-3-Oxoandrost-4-en-17-yl tridecanoate to an individual in need of (17-β)-hydroxy-4-androsten-3-one in single or divided doses. 
     
     
         15 . The pharmaceutical composition of  claim 13 , which is a liquid, solution, suspension, dispersion, solid, semi-solid, a gel, a lotion, paste, granule, aggregate, powder, foam, spray, emulsion, syrup, or ointment. 
     
     
         16 . The pharmaceutical composition of  claim 13 , further comprising a stabilizing agent. 
     
     
         17 . The pharmaceutical composition of  claim 13 , further comprising a pharmaceutically is selected from group consisting of acid, base, antioxidant, or desiccant. 
     
     
         18 . The pharmaceutical composition of  claim 13  for formulated for oral administration. 
     
     
         19 . The pharmaceutical composition of  claim 13 , wherein the composition is substantially free of a decomposition product of (17-β)-3-Oxoandrost-4-en-17-yl tridecanoate resulting from oxidation, reduction, cleavage of the ester moiety; oxidation of the steroid ring system; cleavage of one or more rings of the steroid ring system; rearrangement of the steroid ring; dealkylation of the steroid ring; dealkylation of the ester; or a combination thereof. 
     
     
         20 . The pharmaceutical composition of  claim 13 , wherein the potency of the substantially pure (17-β)-3-Oxoandrost-4-en-17-yl tridecanoate is retained to at least 90% of the initial amount added to the composition. 
     
     
         21 . The pharmaceutical composition of  claim 13 , wherein the composition comprises less than 20% of (17-β)-3-Oxoandrost-4-en-17-yl tridecanoate related total known or unknown impurity or decomposition substances. 
     
     
         22 . The pharmaceutical composition of  claim 13 , wherein the composition comprises less than 10% of (17-β)-3-Oxoandrost-4-en-17-yl tridecanoate total known impurity or decomposition substances. 
     
     
         23 . The pharmaceutical composition of  claim 13 , comprising or made from at least 30 mg of substantially pure (17-β)-3-Oxoandrost-4-en-17-yl tridecanoate. 
     
     
         24 . The composition of  claim 13 , wherein the pharmaceutically acceptable carrier comprises at least one additive selected from the group consisting of lipophilic additives and hydrophilic additives. 
     
     
         25 . The composition of  claim 24 , wherein the lipophilic additive includes a constituent selected from the group consisting of lipophilic surfactant(s), triglyceride(s), oil(s), fatty acid(s), fatty acid glyceride(s), tocopherol(s), tocopherol derivative(s), and combinations thereof. 
     
     
         26 . The composition of  claim 24 , wherein the pharmaceutically acceptable carrier comprises at least one constituent selected from the group consisting of hydrophilic triglyceride, hydrophilic surfactant(s), cellulose(s), polyvinyl acetate, polyvinyl alcohol, polyvinylpyrrolidone, vinylpyrrolidone-vinyl acetate copolymer, polyethylene glycol, and combinations thereof. 
     
     
         27 . The pharmaceutical composition of  claim 13  which is formulated as a unit dosage form. 
     
     
         28 . The unit dosage forms of  claim 27 , is a capsule, tablet, solution, drink, sprinkle or a suspension. 
     
     
         29 . The unit dosage form of  claim 28 , is for oral administration. 
     
     
         30 . A unit oral dosage form of  claim 29 , comprising or made from at least 100 mg of substantially pure (17-β)-3-Oxoandrost-4-en-17-yl tridecanoate. 
     
     
         31 - 34 . (canceled) 
     
     
         35 . The pharmaceutical composition of  claim 13 , having a peroxide value of less than 100.